Protara Therapeutics (TARA) Income from Continuing Operations (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Income from Continuing Operations data on file, last reported at 28925000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 58.4% year-over-year to 28925000.0 in Q1 2026; TTM through Mar 2026 was 88760000.0, a 52.32% decrease from a year earlier, with the FY2025 full-year figure at 148061000.0, down 25.13% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 28925000.0, down from 19489000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for TARA reached as high as 9132000.0 in Q3 2022 and fell as low as 40059000.0 in Q4 2022.
• Historically, Income from Continuing Operations has averaged 16516176.47 across 5 years, with a median of 13437000.0 in 2023.
• Across the five-year window, Income from Continuing Operations slumped 225.29% in 2022 and jumped 67.56% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 40059000.0 in 2022, then soared by 67.56% to 12996000.0 in 2023, then gained by 12.45% to 11378000.0 in 2024, then tumbled by 71.29% to 19489000.0 in 2025, then slumped by 48.42% to 28925000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 28925000.0 in Q1 2026, 19489000.0 in Q4 2025, and 19370000.0 in Q3 2025.